Affimed N.V. (AFMD)

NASDAQ: AFMD · IEX Real-Time Price · USD
4.44
0.03 (0.68%)
At close: Jan 14, 2022 4:00 PM
4.51
0.07 (1.58%)
After-hours:Jan 14, 2022 4:49 PM EST
Market Cap531.90M
Revenue (ttm)34.59M
Net Income (ttm)-50.45M
Shares Out119.80M
EPS (ttm)-0.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume990,234
Open4.36
Previous Close4.41
Day's Range4.20 - 4.45
52-Week Range4.20 - 11.74
Beta2.50
AnalystsStrong Buy
Price Target12.67 (+185.3%)
Earnings DateNov 10, 2021

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical s...

IndustryBiotechnology
IPO DateSep 12, 2014
Employees153
Stock ExchangeNASDAQ
Ticker SymbolAFMD
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 7 analysts, the average rating for Affimed stock is "Strong Buy." The 12-month stock price forecast is 12.67, which is an increase of 185.25% from the latest price.

Price Target
$12.67
(185.25% upside)
Analyst Consensus: Strong Buy

News

Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provide...

HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...

1 week ago - GlobeNewsWire

Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference

HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

1 week ago - GlobeNewsWire

Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology An...

HEIDELBERG, Germany, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

1 month ago - GlobeNewsWire

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.

1 month ago - Zacks Investment Research

Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-d...

HEIDELBERG, Germany, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer will h...

1 month ago - GlobeNewsWire

Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's...

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announ...

1 month ago - GlobeNewsWire

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

These eight stocks could rebound nicely over the next year and beyond.

1 month ago - The Motley Fool

3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale

Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.

Other symbols:AMGNBMY
1 month ago - The Motley Fool

Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose

Affimed NV (NASDAQ:AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. Eighte...

1 month ago - Benzinga

Why Affimed Stock Is On Fire Today

The biotech's early-stage trial results are turning heads on Wall Street today.

1 month ago - The Motley Fool

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Kille...

HEIDELBERG, Germany, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

1 month ago - GlobeNewsWire

Why Affirmed Stock Was Up More Than 12% Wednesday

Positive trial results regarding the company's pipeline are buoying the stock's price.

1 month ago - The Motley Fool

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstr...

HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

2 months ago - GlobeNewsWire

Affimed N.V. (AFMD) Reports Q3 Loss, Lags Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -30.77% and -13.34%, respectively, for the quarter ended September 2021.

2 months ago - Zacks Investment Research

Recap: Affimed Q3 Earnings

Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

2 months ago - Benzinga

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

HEIDELBERG, Germany, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

2 months ago - GlobeNewsWire

Affimed to Present at Upcoming Investor Conferences

HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...

2 months ago - GlobeNewsWire

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate C...

HEIDELBERG, Germany and SANTA ANA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) and NKGen Biotech, both clinical stage biotech companies focused on harnessing the power of the b...

2 months ago - GlobeNewsWire

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...

2 months ago - GlobeNewsWire

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and C...

HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

2 months ago - GlobeNewsWire

Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?

Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 months ago - Zacks Investment Research

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

2 months ago - GlobeNewsWire

2 Biotech Stocks Set to Go Supernova Soon

Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

Other symbols:AVXL
2 months ago - The Motley Fool

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual ...

HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for September 29th

AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.

Other symbols:BCEFSLRMUUSNA
3 months ago - Zacks Investment Research